B（1〜3か月） phage P1 LoxP sites, Mus musclus phosphoglycerate kinase promoter (PGK promoter), Escherichia coli Neomycin resistance gene, mouse Ret genomic DNA, Escherichia coli LacZ gene, mouse Ptch1 genomic DNA B6.Cg-Ret<tm1Mat> Ptch1<tm1Mps> B6.Cg-Ret<tm1Mat> Ptch1<tm1Mps> Ret Y1062F knock-in and Ptch1 KO double mutant mice. The Ret Y1062F knock-in allele consists of two amino acid replacement (KLY<1062> to KIF<1062>) within exon 19 and a floxed PGK-neo cassette inserted into intron 19. Part of exon 1 and all of exon 2 of Ptch1 gene were replaced with a lacZ-neo cassette in the Ptch1 KO allele. Masashi KATO Prior to requesting the BIOLOGICAL RESOURCE, the RECIPIENT must obtain approval from the DEPOSITOR using the Approval Form. For use of the BIOLOGICAL RESOURCE by a for-profit institution, the RECIPIENT must reach agreement on terms and conditions of use of it with DEPOSITOR and must obtain a prior written consent from the DEPOSITOR. The RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE. Ret YF; Ptch1 KO, B6-RetYF KI/Ptch1 KO Ret YF; Ptch1 KO, B6-RetYF KI/Ptch1 KO 条件を付加する。利用者は提供承諾書を用いて、事前に寄託者の承諾を得る。<br>営利機関の利用希望者は、事前に利用条件等につき寄託者と合意し、提供承諾を得ること。利用者が本件リソースを使用して得られた研究成果に基づき特許等の申請、及び事業活動を行う場合は、寄託者と別途協議を行う。 Cre/loxP system Fluorescent Proteins/lacZ System Necessary documents for ordering:<ol><li>Approval form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_6.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_d.docx">English</A>)</li><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Category I MTA: MTA for distribution with RIKEN BRC (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_5.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx">English</A>)</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li></ol> 加藤　昌志 Ret遺伝子にY1062F変異を挿入したノックインアレルとPtch1遺伝子のノックアウトアレル (エクソン1の一部とエクソン2をlacZ-neoカセットで置換) をもつダブルミュータント系統。 true Ret遺伝子にY1062F変異を挿入したノックインアレルとPtch1遺伝子のノックアウトアレル (エクソン1の一部とエクソン2をlacZ-neoカセットで置換) をもつダブルミュータント系統。, <a href='https://brc.riken.jp/mus/pcr06251'>Genotyping protocol -PCR-</a> Ret: Heterozygote x Wild-type; Ptch1: Heterozygote x Wild-type [or Crossing to C57BL/6JJmsSlc] Ret: Heterozygote x Wild-type; Ptch1: Heterozygote x Wild-type [or Crossing to C57BL/6JJmsSlc] Ret Y1062Fノックイン：名古屋大学大学院医学系研究科・高橋雅英。Ptch1 KO：Stanford University School of Medicine・Dr. Matthew Scott。 Ret Y1062F knock-in: Developed by Masahide Takahashi, Nagoya University Graduate School of Medicine. Ptch1 KO: Developed by Matthew Scott, Stanford University School of Medicine. B (1-3 months) RBRC06251